Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts TNXP Hot Sheet
Price: $5.17 +0.78%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Roth Capital downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.00 (from $6.00).
Analyst Scott Henry cites the disappointing results form the interim Phase 3 review of Tonmya for the downgrade.
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $3.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- CoreWeave (CRWV) PT Lowered to $105 at UBS
- FirstService Corp (FSV) PT Lowered to $179 at BMO Capital
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Downgrades, Hot DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
